La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ESSA Pharma Croissance future

Future contrôle des critères 0/6

Les bénéfices de ESSA Pharma devraient diminuer de 12.9% par an tandis que son chiffre d'affaires annuel devrait croître de 82.8% par an. Le BPA devrait croître de en baisse de 13.2% par an.

Informations clés

-12.6%

Taux de croissance des bénéfices

-12.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.0%
Taux de croissance des recettes	82.7%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	28 Aug 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:EPIX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2026	5	-70	-94	N/A	5
9/30/2025	N/A	-47	-63	N/A	5
9/30/2024	N/A	-32	-32	N/A	5
6/30/2024	N/A	-28	-24	-24	N/A
3/31/2024	N/A	-28	-23	-23	N/A
12/31/2023	N/A	-26	-22	-22	N/A
9/30/2023	N/A	-27	-20	-20	N/A
6/30/2023	N/A	-27	-23	-23	N/A
3/31/2023	N/A	-29	-24	-24	N/A
12/31/2022	N/A	-33	-27	-27	N/A
9/30/2022	N/A	-35	-28	-28	N/A
6/30/2022	N/A	-37	-28	-28	N/A
3/31/2022	N/A	-37	-28	-28	N/A
12/31/2021	N/A	-39	-27	-27	N/A
9/30/2021	N/A	-37	-25	-25	N/A
6/30/2021	N/A	-33	-22	-22	N/A
3/31/2021	N/A	-29	-19	-19	N/A
12/31/2020	N/A	-25	-18	-18	N/A
9/30/2020	N/A	-23	-17	-17	N/A
6/30/2020	N/A	-22	-18	-18	N/A
3/31/2020	N/A	-21	-17	-17	N/A
12/31/2019	N/A	-15	-14	-14	N/A
9/30/2019	N/A	-13	-12	-12	N/A
6/30/2019	N/A	-12	-9	-9	N/A
3/31/2019	N/A	-11	-10	-10	N/A
12/31/2018	N/A	-12	-10	-10	N/A
9/30/2018	N/A	-12	-10	-10	N/A
6/30/2018	N/A	-11	-11	-11	N/A
3/31/2018	N/A	-5	N/A	-13	N/A
12/31/2017	N/A	-8	N/A	-13	N/A
9/30/2017	N/A	-4	N/A	-17	N/A
6/30/2017	N/A	-7	N/A	-18	N/A
3/31/2017	N/A	-14	N/A	-16	N/A
12/31/2016	N/A	-8	N/A	-19	N/A
9/30/2016	N/A	-13	N/A	-15	N/A
6/30/2016	N/A	-8	N/A	-17	N/A
3/31/2016	N/A	-10	N/A	-18	N/A
12/31/2015	N/A	-12	N/A	-14	N/A
9/30/2015	N/A	-10	N/A	-13	N/A
6/30/2015	N/A	-11	N/A	-10	N/A
3/31/2015	N/A	-6	N/A	-5	N/A
12/31/2014	N/A	-3	N/A	-4	N/A
9/30/2014	N/A	-2	N/A	-2	N/A
6/30/2014	N/A	-1	N/A	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: EPIX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: EPIX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: EPIX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: EPIX ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: EPIX ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de EPIX devrait être élevé dans 3 ans

ESSA Pharma Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma Inc., Annual General Meeting, Mar 06, 2024

New major risk - Revenue and earnings growth

Independent Director recently bought US$135k worth of stock

New major risk - Share price stability

Independent Director recently bought US$420k worth of stock

ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

High number of new directors

Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors

Now 21% undervalued after recent price drop

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Now 23% undervalued

Independent Director notifies of intention to sell stock

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2023

ESSA Pharma Inc. Provides an Update on Its Clinical Collaboration with Janssen

Insufficient new directors

ESSA Pharma Inc. Announces Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

ESSA Pharma Inc. Appoints Philip Kantoff to its Board of Directors

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

ESSA Pharma Inc. Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Inc., Annual General Meeting, Mar 09, 2022

ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients

ESSA Pharma Inc. Enters into Clinical Collaboration and Supply Agreement with Astellas Pharma Inc. to Evaluate Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc. has completed a Follow-on Equity Offering in the amount of $130.434786 million.

ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

ESSA Pharma EPS beats by $0.02

ESSA Pharma Inc. Announces Voluntary Delisting from the TSX-V

New 90-day low: US$6.10

Independent Chairman of the Board recently bought US$37k worth of stock

Essa Pharma Inc. Announces the Presentation of Data of ESSA's Clinical Candidate, EPI-7386, at the ESMO Virtual Congress 2020

New 90-day high - US$7.64

Independent Director recently bought US$551k worth of stock

New 90-day high - US$7.06

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance